Ich stimme zu, dass diese Seite Cookies verwende. Weitere Informationen finden Sie unter unseren Datenschutzerklärungen .
X
de Kimpe, S.J.
96  Ergebnisse:
Personensuche X
?
1

Evaluation of serum MMP-9 as predictive biomarker for antis..:

Lourbakos, A. ; Yau, N. ; de Bruijn, P....
Scientific Reports.  7 (2017)  1 - p. , 2017
Link: https://doi.org/10.1038/..
 
?
2

Comparing biomarker expression between sub-populations of D..:

Boekhoorn, K. ; Beekman, C. ; van Wijngaarden, S....
Neuromuscular Disorders.  26 (2016)  - p. S158-S159 , 2016
Link: https://doi.org/10.1016/..
 
?
3

P.13.12 An objective method for immunofluorescence analysis..:

Beekman, C. ; Testerink, J. ; Giannakopoulos, S....
Neuromuscular Disorders.  23 (2013)  9-10 - p. 812 , 2013
Link: https://doi.org/10.1016/..
 
?
4

P.11.21 Bioanalysis of a double blind, placebo-controlled c..:

Lourbakos, A. ; Beekman, C. ; Holling, T....
Neuromuscular Disorders.  23 (2013)  9-10 - p. 805 , 2013
Link: https://doi.org/10.1016/..
 
?
5

T.I.2 Exon skipping and PRO044 in Duchenne muscular dystrop..:

Ferlini, A. ; Goemans, N. ; Tulinius, M....
Neuromuscular Disorders.  23 (2013)  9-10 - p. 847 , 2013
Link: https://doi.org/10.1016/..
 
?
6

O.11 Personalized therapy in Duchenne muscular dystrophy: A..:

Campion, G. ; Voit, T. ; Levin, A.A....
Neuromuscular Disorders.  23 (2013)  9-10 - p. 848 , 2013
Link: https://doi.org/10.1016/..
 
?
7

Increasing Evidence-Based Workplace Health Promotion Best P..:

Laing, SS ; Hannon, PA ; Talburt, A...
Preventing Chronic Disease.  , 2012
Link: https://doi.org/10.5888/..
 
?
8

2FC2.1 Phase I/IIa Extension Study of PRO051/GSK2402968 in ..:

Goemans, N. ; Tulinius, M. ; Wilson, R....
European Journal of Paediatric Neurology.  15 (2011)  - p. S19-S20 , 2011
Link: https://doi.org/10.1016/..
 
?
9

P4.27 Fourty eight-week follow-up data from a Phase I/IIa e..:

Goemans, N.M.L. ; Tulinius, M. ; van den Hauwe, M....
Neuromuscular Disorders.  21 (2011)  9-10 - p. 712 , 2011
Link: https://doi.org/10.1016/..
 
?
10

P4.18 Prednisolone treatment does not influence antisense-m..:

Verhaart, I.E.C. ; Heemskerk, J.A. ; de Kimpe, S....
Neuromuscular Disorders.  21 (2011)  9-10 - p. 709 , 2011
Link: https://doi.org/10.1016/..
 
?
11

O.15 24 week follow-up data from a phase I/IIa extension st..:

Goemans, N. ; Tulinius, M. ; Buyse, G....
Neuromuscular Disorders.  20 (2010)  9-10 - p. 639 , 2010
Link: https://doi.org/10.1016/..
 
?
12

O01 An overview of RNA therapeutics:

van Ommen, G.-J.B. ; Aartsma-Rus, A. ; van Putten, M....
Neuromuscular Disorders.  20 (2010)  - p. S1 , 2010
Link: https://doi.org/10.1016/..
 
?
13

T.O.4 A phase I/IIa study on antisense compound PRO051 in p..:

Goemans, N.M. ; Buyse, G. ; Tulinius, M....
Neuromuscular Disorders.  19 (2009)  8-9 - p. 659-660 , 2009
Link: https://doi.org/10.1016/..
 
?
14

T.P.2.05 Direct comparison of 2′O-methyl and PMO AONs for e..:

Heemskerk, H.A. ; de Winter, C.L. ; de Kimpe, S.J....
Neuromuscular Disorders.  18 (2008)  9-10 - p. 757 , 2008
Link: https://doi.org/10.1016/..
 
?
15

T.P.2.04 Optimization of antisense-mediated exon skipping i..:

Aartsma-Rus, A. ; Heemskerk, H.A. ; de Winter, C.L....
Neuromuscular Disorders.  18 (2008)  9-10 - p. 757 , 2008
Link: https://doi.org/10.1016/..
 
1-15